Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Long Grove Pharmaceuticals in-licensed Norepinephrine Bitartrate in 0.9% Sodium Chloride premix formulation, indicated to raise blood pressure in adult patients with severe, acute hypotension, from Nevakar Injectables.
Lead Product(s): Norepinephrine Bitartrate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: NVK004
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Nevakar
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 04, 2023